Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Carsten Rohde Med Vet x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine the effects of phenylbutazone (PBZ) on bone activity and bone formation in horses.

Animals—12 healthy 1- to 2-year-old horses.

Procedures—Biopsy was performed to obtain unicortical bone specimens from 1 tibia on day 0 and from the contralateral tibia on day 14. Fluorochromic markers were administered IV 2 days prior to and on days 0, 10, 15, and 25 after biopsy was performed. Six horses received PBZ (4.4 mg/kg of body weight, PO, q 12 h) and 6 horses were used as controls. All horses were euthanatized on day 30 and tissues from biopsy sites, with adjacent cortical bone, were collected. Osteonal density and activity, mineral apposition rate (MAR), and percentage of mineralized tissue filling the biopsy-induced defects in cortical bone were assessed. Serum samples from all horses were analyzed for bone-specific alkaline phosphatase activity and concentration of PBZ.

Results—MAR was significantly decreased in horses treated with PBZ. Regional acceleratory phenomenon was observed in cortical bone in both groups but was significantly decreased in horses treated with PBZ. Osteonal activity was similar at all time points in all horses. In control horses, percentage of mineralized tissue filling the cortical defects was significantly greater in defects present for 30 days, compared with defects present for 14 days. Differences in percentage of mineralized tissue were not detected in horses treated with PBZ.

Conclusions and Clinical Relevance—PBZ decreased MAR in cortical bone and appeared to decrease healing rate of cortical defects in horses. (Am J Vet Res 2000;61:537–543)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To isolate and characterize bone marrow–derived equine mesenchymal stem cells (MSCs) for possible future therapeutic applications in horses.

Sample Population—Equine MSCs were isolated from bone marrow aspirates obtained from the sternum of 30 donor horses.

Procedures—Cells were cultured in medium (alpha-minimum essential medium) with a fetal calf serum content of 20%. Equine MSC features were analyzed to determine selfrenewing and differentiation capacity. For potential therapeutic applications, the migratory potential of equine MSCs was determined. An adenoviral vector was used to determine the transduction rate of equine MSCs.

Results—Equine MSCs can be culture-expanded. Equine MSCs undergo cryopreservation in liquid nitrogen without altering morphologic characteristics. Furthermore, equine MSCs maintain their ability to proliferate and differentiate after thawing. Immunocytochemically, the expression of the stem cell marker CD90 can be detected on equine MSCs. The multilineage differentiation potential of equine MSCs was revealed by their ability to undergo adipogenic, osteogenic, and chondrogenic differentiation.

Conclusions and Clinical Relevance—Our data indicate that bone marrow–derived stromal cells of horses can be characterized as MSCs. Equine MSCs have a high transduction rate and migratory potential and adapt to scaffold material in culture. As an autologous cell population, equine MSCs can be regarded as a promising cell population for tissue engineering in lesions of the musculoskeletal system in horses.

Full access
in American Journal of Veterinary Research